Viking Therapeutics GLP-1 obesity drug shows 22% weight loss
Viking Therapeutics said its experimental GLP-1 obesity drug helped patients lose 22% of body weight after 33 weeks of weekly treatment in a maintenance study.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.